北京九强生物技术股份有限公司 关于2025年第四季度可转换公司债券转股情况的公告 | 证券代码：300406 | 证券简称：九强生物 | 公告编号：2026-001 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"九强转债"（债券代码：123150）的转股期限为 2023 年 1 月 6 日至 2028 年 6 月 29 日；最新有效的转股价格为 16.48 元/股。 2、2025 年第四季度，"九强转债"未发生转股情况。 （二）可转债上市情况 经深圳证券交易所同意，公司本次发行的可转换公司债券于 2022 年 7 月 20 日起在深圳证券交易所挂牌交易，债券代码"123150"，债券简称"九强转债"。 （三）可转债转股期限 3、截至 2025 年第四季度末，公司剩余可转债为 11,210,221 张，剩余票面 总金额为 1,121,022,100 元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引 ...

Core Viewpoint - Jiukang Bio's stock price has shown a slight increase of 2.07% this year, but has experienced a decline over the past five and twenty trading days, indicating potential volatility in its stock performance [1]. Group 1: Stock Performance - As of January 5, Jiukang Bio's stock price reached 13.34 yuan per share, with a market capitalization of 7.821 billion yuan [1]. - The stock has seen a 2.07% increase year-to-date, a 0.60% decrease over the last five trading days, a 1.84% decrease over the last twenty days, and a 0.75% increase over the last sixty days [1]. Group 2: Financial Performance - For the period from January to September 2025, Jiukang Bio reported a revenue of 1.012 billion yuan, representing an 18.24% year-on-year decrease, and a net profit attributable to shareholders of 272 million yuan, down 27.03% year-on-year [2]. - Cumulatively, since its A-share listing, Jiukang Bio has distributed a total of 1.33 billion yuan in dividends, with 701 million yuan distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, Jiukang Bio had 18,100 shareholders, a decrease of 2.48% from the previous period, with an average of 23,502 circulating shares per shareholder, an increase of 2.54% [2]. - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF held 8.3446 million shares, a decrease of 1.4085 million shares compared to the previous period [3]. Group 4: Business Overview - Jiukang Bio, established on March 29, 2001, and listed on October 30, 2014, specializes in the research, production, and sales of biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology testing [1]. - The company's main revenue sources include in vitro diagnostic reagents (95.09%), in vitro testing instruments (3.06%), other business income (0.96%), inspection services (0.53%), and instrument leasing income (0.36%) [1].

Regulatory Developments - The National Medical Products Administration (NMPA) held a meeting on post-market regulation of medical devices, emphasizing the need for a balance between safety and industry vitality while planning for 2026 [1] - The NMPA approved the long-acting growth hormone injection, Nozeyou®, developed by Novo Nordisk, marking it as the first international original long-acting growth hormone for children in China [4] - Changchun High-tech's subsidiary, GenSci, received acceptance for a clinical trial application for GenSci141 ointment, which aims to address various hormonal deficiencies in children [5] - Jiukang Bio announced the acquisition of medical device registration certificates for two diagnostic kits, enhancing its product line in the in vitro diagnostic sector [6] Market Activities - Suzhou Tongxin Medical Technology's IPO application was accepted, with plans to raise 1.064 billion yuan for various projects including the production base for implantable left ventricular assist devices [8][9] - Zhendong Pharmaceutical announced a partnership to establish a fund focused on investments in the biopharmaceutical sector, contributing 30 million yuan as a limited partner [11] Corporate Changes - Baihua Pharmaceutical is planning a change in control, leading to a temporary suspension of its stock trading [10] - *ST Changyao is under investigation for alleged financial misconduct, which may lead to a forced delisting due to false financial reporting [18]

智通财经APP讯，九强生物(300406.SZ)发布公告，公司及全资子公司北京美创新跃医疗器械有限公司 (以下简称"美创新跃")于近日收到北京市药品监督管理局颁发的《医疗器械注册证》，涉及产品："丙氨 酸氨基转移酶测定试剂盒(丙氨酸底物法)"、"D-二聚体测定试剂盒(胶乳免疫比浊法)"。 ...

人民财讯12月26日电，九强生物（300406）12月26日公告，公司及全资子公司北京美创新跃医疗器械有 限公司近日收到北京市药品监督管理局颁发的《医疗器械注册证》，两款产品名称为丙氨酸氨基转移酶 测定试剂盒(丙氨酸底物法)、D-二聚体测定试剂盒(胶乳免疫比浊法)。 ...

九强生物公告，公司及全资子公司北京美创新跃医疗器械有限公司近日收到北京市药品监督管理局颁发 的《医疗器械注册证》。产品名称为丙氨酸氨基转移酶测定试剂盒（丙氨酸底物法）和D-二聚体测定 试剂盒（胶乳免疫比浊法），注册类别为Ⅱ类，注册证有效期自批准之日起至2030年12月21日和2030年 12月18日。上述产品医疗器械注册证的取得，丰富了公司在体外诊断生化及血凝细分领域产品线的品 种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经营将产生积极影响。 ...

特此公告。 北京九强生物技术股份有限公司 关于公司及全资子公司取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"或"九强生物"） 及全资子公司北京美创新跃医疗器械有限公司（以下简称"美创新跃"）于 近日收到北京市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 1 | 丙氨酸氨基 转移酶测定 试剂盒（丙氨 | 京械注准 20252401017 | Ⅱ | 自批准之日起 有效期至2030 年 12 月 21 日 | 本试剂盒用于体外定 量测定人血清中丙氨 酸氨基转移酶（谷丙转 | 九强生物 | | --- | --- | --- | --- | --- | --- | --- | | | 酸底物法） | | | | 氨酶，ALT）含量。 | | | 2 | D-二聚体测 定试剂盒（胶 乳免疫比浊 | 京械注准 20252401004 | Ⅱ | 自批准之日起 有效期至2030 | 本试剂盒用于体外定 量测定人血浆中的 D- 二聚体（D-Dimer)的含 | 美创新跃 | | | 法 ...

Group 1 - The company is focusing on advancing product registration and distribution channel development in key markets such as Europe, the United States, and Southeast Asia [1] - There is an increasing demand from overseas medical institutions for precise diagnostics and digital pathology, indicating a growing market opportunity [1] - The company has a solid foundation in software and hardware, positioning it well for international expansion in the field of pathology AI [1] Group 2 - The company emphasizes a clinical value-oriented approach and will continue to promote business collaborations with well-known leading companies [1] - Investors have inquired about the company's progress in expanding into overseas markets and the potential for AI pathology diagnostic technology to develop internationally [3] - Questions have been raised regarding the possibility of collaboration with major tech companies like Alibaba and Tencent [3]

九强生物（300406.SZ）12月24日在投资者互动平台表示，指南的发布，从政策层面认可AI在病理诊断 中的应用价值，为病理数字化和新技术应用提供了制度基础，有阶段性积极意义。病理AI相关项目是 公司重点研发项目，当前，在研产品尚处于临床验证阶段，后续相关进展请以公司公告为准。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：国家医保局12月19日发布的病理检查诊断价格立项精 细化文件对公司的AI病理诊断是利好么？目前子公司迈新生物的AI病理诊断涵盖了多少省市和医院？ 公司的AI病理诊断准确率有多高？ ...

Group 1 - Jizhi Co., Ltd. plans to acquire at least 51% equity in Pumai Technology through cash payment, aiming to gain control over the company, which is a leading enterprise in the field of robot performance testing and calibration in China [1] - Yaxing Chemical's subsidiary intends to transfer 7.14% equity for 60 million yuan to another fund under the same control, indicating strategic investment movements within the same management group [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Sentai Co., Ltd.'s controlling shareholder plans to increase shareholding by at least 100 million yuan within 12 months, aiming to enhance confidence in the company's future [4] - Health元's subsidiary has received acceptance for the marketing authorization application of Lecanemab injection, which is intended for moderate to severe plaque psoriasis patients [5][11] - Sunshine Nuohuo has signed a technical development contract for the STC008 injection project, with a total payment of 500 million yuan, indicating significant investment in cancer treatment [6] Group 3 - Hunan YN has been designated as a delivery warehouse for lithium carbonate by the Guangzhou Futures Exchange, enhancing its position in the lithium market [7] - Tianji Co., Ltd. is pushing for the industrialization of lithium sulfide material preparation, although it faces risks in commercialization [8] - Yuandong Bio has received FDA approval for Methylene Blue injection, expanding its product portfolio in the U.S. market [10] Group 4 - Nanshan Aluminum has established a wholly-owned subsidiary in Hainan with an investment of 5 million yuan, focusing on high-end aluminum products [13] - ST Xifa plans to acquire 50% equity in Lhasa Beer, aiming for full ownership, with the transaction currently in the planning stage [14] - Hengrui Medicine's SHR-A1904 injection has been included in the list of breakthrough therapy products, indicating its potential in treating advanced gastric cancer [12] Group 5 - Chengdu Gas is planning to merge three subsidiaries, streamlining operations and enhancing efficiency [26] - Baoli Electric intends to invest 50 million yuan to establish a wholly-owned subsidiary focused on key equipment and solutions in energy storage [27] - Huadian International has successfully put the second unit of its Longkou Phase IV project into commercial operation, marking a significant milestone in its energy production capacity [34]